Combating Illicit Xylazine Act
- Last Action
- 6/25/2026
Actions
- 2026-07-21Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 48 - 0.
- 2026-07-21Committee Consideration and Mark-up Session Held
- 2026-07-20Committee Consideration and Mark-up Session Held
- 2026-06-25Forwarded by Subcommittee to Full Committee by Voice Vote.
- 2026-06-25Subcommittee Consideration and Mark-up Session Held
- 2025-02-12Referred to the Subcommittee on Health.
- 2025-02-12Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-12Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-12Introduced in House
- 2025-02-12Introduced in House
CRS Summary
As of 2025-02-12 (00)
Combating Illicit Xylazine Act
This bill regulates xylazine under the Controlled Substances Act (CSA).
Xylazine, also known as tranq, is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine.
This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused.
Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA.
The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs.
The bill also exempts xylazine manufacturers from the CSA's physical security requirements.
Finally, the bill requires the DEA, in coordination with the Food and Drug Administration, to report on (1) the prevalence and impact of illicit xylazine use in the United States, and (2) updated information on the prevalence and proliferation of xylazine trafficking and misuse in the United States.
Cosponsors (20)
- August Pfluger (R-TX)
- Gus Bilirakis (R-FL)
- Chris Pappas (D-NH)
- Scott Fitzgerald (R-WI)
- Deborah Ross (D-NC)
- Dan Crenshaw (R-TX)
- Josh Harder (D-CA)
- Suzan DelBene (D-WA)
- Mariannette Miller-Meeks (R-IA)
- Brittany Pettersen (D-CO)
- Yvette Clarke (D-NY)
- Christopher Deluzio (D-PA)
- Seth Magaziner (D-RI)
- Don Bacon (R-NE)
- Jay Obernolte (R-CA)
- Jim Costa (D-CA)
- Troy Balderson (R-OH)
- Nanette Barragán (D-CA)
- Juan Ciscomani (R-AZ)
- Mike Carey (R-OH)
Subjects
- Congressional oversight
- Consumer affairs
- Criminal procedure and sentencing
- Drug safety, medical device, and laboratory regulation
- Drug trafficking and controlled substances
- Licensing and registrations
- Manufacturing
- U.S. Sentencing Commission
- Veterinary medicine and animal diseases
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.